Adderall vs Vyvanse: What the Evidence Says About Each

You have been prescribed an amphetamine-based medication for ADHD, or you are about to be, and you have a question: which one? The two most commonly prescribed in the US are Adderall (mixed amphetamine salts) and Vyvanse (lisdexamfetamine), and the internet has strong opinions about both. The evidence has more measured ones.

This is a question that comes with a particular kind of anxiety. You waited months or years for a diagnosis, and now a clinician has said “stimulant medication” and you are sitting with a prescription pad and a decision that feels more consequential than it probably is. The good news: both of these medications work, the evidence for both is strong, and the differences between them are more about delivery than about whether they help.

What they share

Both Adderall and Vyvanse are amphetamine-based. They work by increasing dopamine and norepinephrine availability in the prefrontal cortex and reward pathways, the circuits that manage the executive function deficits at the core of ADHD. The 2018 Lancet Psychiatry meta-analysis, which is the largest comparative study to date, grouped amphetamine medications together as the most effective class for adult ADHD [1]. Head-to-head, they are more alike than different.

Both are first-line treatment options recommended by the European Consensus Statement. Both have large effect sizes, with standardized mean differences around 0.79 versus placebo, which is substantially larger than most psychiatric medications achieve. Both have decades of accumulated clinical experience. The amphetamine molecule doing the work in both cases is dextroamphetamine; the question is how the medication gets it into your system and over what timeframe.

Both also share the same general side effect profile, because the active molecule is the same. Appetite suppression, difficulty sleeping if the medication is active at bedtime, dry mouth, and a slight increase in heart rate and blood pressure. These are dose-dependent effects, meaning they tend to be more pronounced at higher doses and often manageable with dose adjustment.

How they differ

The difference is in the engineering of the pill, not in the pharmacology of the active ingredient.

Adderall (brand and generic) contains a mixture of four amphetamine salts: 75% dextroamphetamine and 25% levoamphetamine. Adderall IR (immediate-release) lasts 4-6 hours. Adderall XR uses a beaded capsule that delivers two pulses: one immediately and one about four hours later, extending the duration to roughly 10-12 hours. The two-pulse design means there are two distinct periods of rising drug levels. Some people experience this as a noticeable “on/off” transition; others prefer it because the second pulse provides a distinct afternoon renewal.

Vyvanse (lisdexamfetamine) is a prodrug. The active molecule, dextroamphetamine, is bonded to the amino acid lysine. After you swallow it, enzymes in the blood cleave the lysine, gradually releasing dextroamphetamine [3]. This enzymatic conversion rate-limits the absorption. You cannot speed it up by crushing the capsule or taking it differently, because the conversion happens in the bloodstream, not the stomach. The result is a smoother onset and a duration of roughly 12-14 hours.

The practical difference is in the curve. Adderall XR produces two distinct peaks; Vyvanse produces a single gradual rise and fall. The Vyvanse curve is often described by clinicians as smoother, with a less noticeable transition between “on” and “off.” For people who are sensitive to the peaks and valleys, who notice a distinct ramp-up in the morning or a crash in the afternoon, the prodrug mechanism can feel more even. For people who prefer a clear second wind in the afternoon, Adderall XR’s two-pulse model may be preferable.

The levoamphetamine component in Adderall is also worth noting. It is a less potent isomer that contributes more to peripheral sympathetic effects (slightly more effect on heart rate and blood pressure) and has a longer duration than dextroamphetamine alone. Whether this makes a clinical difference for a given person is individual.

Efficacy: what the trials show

Adler and colleagues’ phase 3 trial of lisdexamfetamine in 420 adults found significant improvement in ADHD symptoms compared to placebo [2]. The effect sizes were comparable to those seen in Adderall XR trials, and the meta-analytic evidence groups both medications within the same efficacy class [5].

The Cortese et al. meta-analysis, which covered 133 randomized controlled trials and over 8,000 adults, did not find amphetamines to differ meaningfully from one another [1]. The differences that exist between individuals on these medications are larger than the average differences between the medications themselves. Your response to Adderall versus Vyvanse is likely to depend on your individual pharmacology more than on the aggregate trial data.

Misuse potential

Vyvanse was specifically designed to have lower misuse potential. Jasinski and Krishnan’s study of 36 subjects compared the subjective effects of lisdexamfetamine against immediate-release dextroamphetamine at equivalent doses [4]. Lisdexamfetamine produced significantly lower “drug liking” scores because the prodrug mechanism prevents the rapid peak that produces euphoria. Taking more does not override the enzymatic rate-limit; it extends the duration rather than increasing the peak.

This does not mean Vyvanse cannot be misused. It is still a Schedule II controlled substance. But the prodrug design makes it less amenable to the pattern of misuse associated with immediate-release stimulants, which is why some clinicians consider it first when prescribing history or context makes misuse potential a relevant consideration.

How to decide

The choice between Adderall and Vyvanse is typically clinical, not ideological. It is also, for many people, not permanent; switching between stimulant formulations is one of the most common adjustments in ADHD treatment. Factors include:

Duration of coverage needed. If you need symptom management for 10-12 hours, Adderall XR and Vyvanse both cover that range, with Vyvanse extending slightly longer. If you need shorter coverage with more timing control, Adderall IR allows flexibility. Some clinicians prescribe a long-acting formulation with a small IR dose for late-afternoon coverage when the extended-release wears off.

Side effect response. Because the active molecule is the same (dextroamphetamine, with Adderall adding levoamphetamine), side effects are similar. Individual response varies. Some people tolerate one better than the other, and switching is a standard clinical approach. Appetite suppression and sleep disruption are the most common reasons for trying the alternative.

Insurance and cost. Adderall has generic versions, which are significantly less expensive. Vyvanse went generic in the US in 2023, reducing the cost difference, but pricing still varies by insurer. Cost should not determine the choice on its own, but it is a practical factor that clinicians and patients consider.

History of substance use. Clinicians may prefer Vyvanse for patients where misuse potential is a consideration, because of the prodrug mechanism.

The meta-analytic evidence does not favor one over the other for efficacy [1] [5]. The choice is about fit, not superiority. If the first one does not work well, that is information, not failure. Trying the other is a standard next step.

Where the evidence is thin

Direct head-to-head trials between Adderall XR and Vyvanse in adults are limited. Most of the comparative evidence comes from indirect comparison through meta-analyses, which group them by class rather than comparing them directly. Long-term comparative studies, following adults on each medication for years, are essentially absent. Clinical experience fills the gap, but it would be better to have the trials.

We also lack good evidence on which patient characteristics predict a better response to one formulation versus the other. The current approach is empirical: start with a first-line option, adjust dose, switch if needed. Pharmacogenomic testing is commercially available but has limited evidence specifically for guiding the Adderall-versus-Vyvanse decision. For now, the best predictor of which will work for you is trying it and seeing.

The shortage question is also worth noting, because it affects the practical decision in ways that clinical trials do not capture. Stimulant medications have experienced periodic supply disruptions in the US, and these disruptions are not evenly distributed across formulations. A person who is stable on one medication may need to switch temporarily because their pharmacy cannot fill the prescription. Knowing that the other option exists, with comparable efficacy and a similar mechanism, makes that transition less alarming. It is still disruptive: changing medication always involves a readjustment period, and the dose equivalence between Adderall and Vyvanse is not a simple one-to-one conversion. But the disruption is manageable, and the evidence supports treating these as interchangeable options within the same efficacy class.

The question of generic availability also continues to evolve. Generic lisdexamfetamine became available in the US in 2023, which changed the cost calculus that had previously favored Adderall for many patients. Whether the generic versions are bioequivalent in the way that matters to individual patients, meaning whether a person who was stable on brand Vyvanse will feel the same on the generic, is a question that the FDA’s bioequivalence standards address at the population level but that individual responses sometimes complicate. Clinicians report that most patients transition without difficulty, but some notice differences in onset or duration. This is not unique to ADHD medication; it is a general pattern with extended-release formulations where the delivery mechanism is part of the clinical effect.

Getting a diagnosis or reviewing your options. If executive dysfunction is significantly affecting your work or daily life, speaking with a doctor about an ADHD assessment may be worthwhile. In the US, CHADD (chadd.org) has resources for adults seeking a diagnosis, including a provider directory. In the UK, the ADHD Foundation and AADD-UK offer guidance on the referral process.